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Immunologic studies in IgA nephropathy. Circulating immune
complexes (CIC) were detected in 43.6% of 78 patients with pri-
mary IgA nephropathy by the solid-phase Clq radioimmunoas-
say. The IC were intermediate (9 to 17S) in size and contained
IgA, IgG, and less commonly 1gM. CIC were often present inter-
mittently, correlating with episodes of macroscopic hematuria.
Elevated serum IgA concentrations (38.7%) did not correlate
with the detection of CIC. Similar findings were observed in sera
samples from patients with Henoch Schonlein purpura and in
IgA glomerulonephritis associated with alcoholic cirrhosis and!
or portal systemic shunts. The factors responsible for the mesan-
gial localization of the IC are not clear, but elevations in serum
antibody titers to respiratory pathogens (mycoplasma pneu-
moniae, herpes virus, influenza), gut flora (E. co/i 07), and bo-
vine serum albumin suggest that common exogenous antigens
may be involved in the pathogenesis. Primary defects in either
mucosal antigen exclusion or reticuloendothelial IC sequestra-
tion are proposed to account for these findings.
Etudes immunologiques dans Ia néphropathie a IgA. Des im-
muns complexes circulants (CIC) ont été dCtectés dans 43,6%
des 78 malades atteints de nephropathie a IgA au moyen du dos-
age radio-immunologique de CIq en phase solide. Ces immuns
complexes sont de taille intermCdiaire (9 a 17 S) et contiennent
de l'IgA de l'IgG et, de facon moms fréquente, de 1'IgM. Les
CIC ne sont souvent presents que de facon intermittente, en cor-
relation avec les episodes d'hématurie macroscopique. Les con-
centrations elevées d'IgA serique (38,7%) ne sont pas corrélées
avec Ia presence de CIC. Des constatations similaires ont été
faites dans Ic serum de malades atteints de purpura de Henoch
Schonlein et dans Ia glomérulonephrite a IgA associée a la cir-
rhose alcoolique et/ou aux derivations portales. Les facteurs re-
sponsables de Ia localisat ion mesangiale de IC ne sont pas clairs
mais les élévations du titre des anticorps sériques aux agents
pathogenes respiratoires (mycoplasma pneumonia, virus de
l'herpes, influenza), a Ia fore intestinale E. coli 07) eta Ia serum
albumine bovine suggèrent que des anticorps exogènes trés ré-
pandus peuvent être impliqués dans la pathogénie. Des deficits
primaires soit de l'exclusion muqueuse des antigènes, soit de la
sequestration réticulo-endothéliale des IC sont proposes pour
rendre compte de ces constatations.
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Since the original description by Berger in 1968
[1], IgA nephropathy (mesangial IgA disease, ne-
phropathy with mesangial IgA-IgG deposits, IgA-
associated glomerulonephritis) has become widely
recognized as a common form of glomerulonephritis
[2—6]. Although it is classically associated with re-
current episodes of macroscopic hematuria, recent
studies have shown the same gomerular lesion in
patients with asymptomatic proteinuria, hyper-
tension, and renal failure [5]. The condition is no
longer regarded as universally benign, and progres-
sion to end-stage renal failure has been well docu-
mented.
Despite these observations, relatively few studies
have concentrated on pathogenesis. There are,
however, several points of reference. First, the im-
munofluorescence and electron microscopic find-
ings are consistent with an immune complex (IC)
form of glomerulonephritis. Similar, although often
transient, mesangial IC deposits have been de-
scribed in experimental serum sickness [7], in rats
given aggregated gammaglobulin [8], and in mice
with lymphocytic choriomeningitis-associated gb-
merulonephritis [9]. Second, the presence of similar
deposits in the skin [10] (Thompson et al, to be pub-
lished), the analogies with Henoch Schonlein pur-
pura (HSP) [5, 6] and the recurrence of IgA ne-
phropathy in grafted kidneys [11] are consistent
with mediation by circulating IC (dC). Indeed,
Wilson and Dixon have postulated that patients with
IgA nephropathy form "showers" of IC during in-
fections and that the participation of preformed
(IgA) antibodies may influence IC size and mesangi-
al localization [12]. Third, it is now recognized that
a similar form of glomerulonephritis occurs com-
monly in patients with alcoholic cirrhosis, with or
without portal systemic shunts [13, 14]. Elevated
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serum IgA concentrations are common to both pri-
mary IgA nephropathy and alcoholic cirrhosis and
have been attributed in the latter to a state of hyper-
immunization secondary to defective hepatic se-
questration of antigens [15]. IgA nephropathy has
also been described in association with celiac dis-
ease where defective antigen exclusion at the gut
mucosa has been invoked [16].
The present study aims to test these observa-
tions, to define the mediation of IgA nephropathy,
and to compare the findings with those seen in HSP
and in glomerulonephnitis associated with alcoholic
cirrhosis.
Methods
Patients (Table 1). Three groups were studied:
Group 1: Primary IgA nephropathy (78 patients).
These patients presented with macroscopic hema-
tuna, asymptomatic proteinuria, hypertension, or
renal insufficiency. All had at least one renal biopsy
sample examined by light, electron, and immuno-
fluorescent microscopy, as previously described
[5]. The patients in this group all had diffuse mesan-
gial deposits of IgA, which were usually accom-
panied by C3 (82%) and less commonly by 1gM
(43%), IgG (22%), and Clq (14%). In all instances,
IgA was the principal immunoglobulin detected.
Light microscopy showed mesangial enlargement
with or without focal and segmental features, and
electron microscopy confirmed the presence of
mesangial deposits and increased mesangial cyto-
plasm and matrix. Details of the morphologic find-
ings in 50 of these patients have been reported pre-
viously [5]. Patients with clinical evidence of liver
disease or of systemic disease (skin rash, arthralgia,
and so on) were excluded as were patients with a
positive test for antinuclear antibodies.
Group 2: IgA glomerulonephritis associated with
alcoholic cirrhosis, portal systemic shunts, or both
(10 patients). The patients in this group had macro-
scopic hematuria, proteinunia, hypertension, or re-
nal insufficiency in association with alcoholic cir-
rhosis and/or portal systemic shunts. Nine had alco-
holic cirrhosis, two with portacaval shunts, and one
patient had a lienorenal shunt for primary portal
vein thrombosis. Renal biopsy findings were gener-
ally similar to those in primary IgA nephropathy.
All patients has mesangial deposits of IgA, and in
addition many had C3 (90%), 1gM (63%), IgG
(50%), and Clq (50%). Electron microscopy demon-
strated mesangial and subendothelial dense depos-
its and, in some patients, the membrane and matrix
lucencies described in glomerulonephritis associat-
ed with alcoholic cirrhosis [13]. None of the pa-
tients was positive for hepatitis B virus antigen or
antibody.
Group 3: Henoch Schonlein purpura (HSP) (6
patients). These patients presented with the charac-
teristic features of skin rash, arthralgia, and glomer-
ulonephritis. In addition, one patient had abdominal
pain and gastrointestinal bleeding. All patients had
mesangial deposits of IgA and C3.
Sera. Blood was collected, if possible, at the time
of the initial renal biopsy and then at 3 to 6 monthly
intervals. Samples (N = 264) were collected from
the 78 patients with primary IgA nephropathy, 57
from the 10 patients in group 2 and 26 from the 6
patients with HSP. Blood samples were also col-
lected from 80 control subjects (hospital staff and
healthy blood donors). The serum was separated by
centrifugation at room temperature and stored in
aliquots at —70° C. Blood samples for the detection
of cryoglobulins (performed in 20 patients) were
collected in a warmed syringe, allowed to clot at 37°
C, and the serum held at 4° C for 3 days.
Serum immuno globulin and complement concen-
trations. Serum IgA, IgG, 1gM, C3, and Clq con-
centrations were measured by radial immuno-
diffusion.
Detection of IgA polymers. Sera samples from 14
patients with primary IgA nephropathy, 6 patients
with alcoholic cirrhosis, and 9 control subjects were
fractionated by column chromatography (Sephadex
G200 or Sepharose CL-6B) and sucrose density gra-
dient ultracentrifugation [17]. Fractions were as-
sayed for IgA, IgG, and 1gM by laser nephelometry
(Hyland).
Detection of CIC. Sera samples were tested for
IC by a modification of the solid-phase Clq radioim-
munoassay (SPC1qA) [18]. Details of the modified
assay have been reported elsewhere [19, 20] and the
only subsequent alteration has been the use of hu-
man serum albumin (HSA) in place of bovine serum
albumin (BSA) as the nonspecific carrier protein. In
the routine assay, iodinated (125!) goat antihuman
IgG (H&L chains) was used to measure the binding
of serum IC to the Clq-coated polystyrene tubes.
Duplicate results were referred to a standard curve
of the binding of heat-aggregated human gam-
maglobulin (AHG), and the amount was expressed
as microgram equivalents per milliliter of serum.
The standard curve was constructed with the same
batch of AHG in the same reference serum in every
assay. The reference serum was selected to corre-
spond to the mean + 2 SD binding in the total con-
trol group, and this set the upper limit of normal in
368 Woodroffe et a!
the assay at 0 g AHG equivalent/mi. Under these
conditions, the following IC prevalence (percent
positive) and quantitation (mean amount in jg AHG
equivalent/mi SD) were detected: (a) normal con-
trols, N = 75 (4.0%, 0.2 0.9); (b) non-IC mediated
renal disease, N = 97 (27 hereditary nephritis, 16
focal glomeruloscierosis, 24 pre-eciamptic toxemia,
6 minimal lesion nephrotic syndrome, 11 anti-
glomerular-basement- membrane- antibody-induced
glomerulonephritis, 13 renal transplant recipients)
(6.2%, 0.6 2.9); (c) type 1 mesangiocapiliary gb-
merulonephritis, N = 20 (45.0%, 15.7 48.7); and
(d) active systemic lupus erythematosus, N = 28
(82.1%, 103.4 125.7).
Determination of IC size. A 1:2 dilution of se-
lected test serum (0.2 ml) was applied to a 10% to
40% linear sucrose gradient (4.0 ml) and centrifuged
for 16 hours at x 300,000g at 4° C. Fractions (0.1 ml
each) were collected from the bottom of the gradi-
ent and tested for IC reactivity by SPC1qA, and for
IgG (7S) and 1gM (l9S) by laser nephelometry.
IdentUication of immunoglobulin class of IC. The
SPC1qA was modified to allow identification of the
class of IC immunoglobulin. Antisera to human
IgA, IgG, and 1gM were freed of antilight-chain re-
activity by immunoabsorption chromatography,
and the monospecificity of the antisera was con-
firmed by immunoelectrophoresis and gel diffusion.
To minimize the reagent volumes, we adapted the
SPCIqA to microtiter plates [21]. Briefly, 0.1 ml of
freshly isolated human Clq (11 pg/mi) was dis-
pensed into each well of plastic microtiter trays
(Cooke microtiter plates, Virginia) and incubated
for 16 hours at 4° C. The trays were then washed,
and 0.2 ml of 1% HSA added and incubated for 2
hours at room temperature. After further washing,
the wells were loaded with 0.1 ml of 1:51 dilution of
test serum pretreated with ethylenediaminetetra-
acetic acid (EDTA) and incubated for 60 mm at 37°
C and 16 hours at 4° C. The trays were washed, and
each test was incubated separately with 0.1 ml of
1251-Iabeled anti-a, anti-y, and anti-p for 60 mm at
37° C and 30 mm at 4° C. After the final washing, the
wells were cut up, and the radioactivity was
counted in a gammacounter. Thirty normal sera
samples were included as controls (mean SD bind-
ing; anti-a 1.00 0.20%, anti-y 1.14 0.15%, and
anti-jt 4.15 0.57%). The reactivity of heat aggre-
gated colostral and myeloma IgA [22] was also de-
termined in this assay.
Identification of specific antibodies. Routine
serologic studies included antinuclear antibody de-
termination, rheumatoid factor (latex test), anti-
bodies to IgA [23], anti-viral antibodies (influenza,
parainfluenza, adenovirus, respiratory syncytial vi-
rus, herpes simplex, and mycoplasma pneumoniae)
hepatitis B virus antigen and antibody, and anti-
streptococcal antibodies (ASOT and ADNaseB). In
addition, sera samples from patients with primary
IgA nephropathy and from patients with alcoholic
cirrhosis were tested for antibodies to Escherichia
co/i (E. co/i) and to BSA. Antibodies toE. coli lipo-
polysaccharide (LPS) serotypes 01, 06, 07, 018, and
075 were measured by hemagglutination with LPS-
coated group-O human red blood cells 124]. Anti-
BSA antibody activity was determined by radioim-
munoassay (RIA). Briefly, 6 /Lg of 1251-labeled BSA
(Caibiochem fraction A) were incubated with 0.1 ml
of a 1:10 dilution of test serum for 30 mm at 37° C
and 60 mm at 4° C. An equal volume of saturated
ammonium sulfate was then added, incubated for 30
mm at 4° C, and the radioactivity in the precipitate
(x 1800g for 15 mm) was counted in a gam-
macounter. In selected sera samples, the immuno-
globulin class of anti-BSA antibody was determined
by a solid-phase RIA with BSA-coated microtiter
plates (0.1 mg of BSA/ml), 1:10 dilution of test
serum, and '251-labeled anti-a, anti-y, and anti-j
antisera as described above for the modified
SPCIqA. Twenty-nine normal sera samples were in-
cluded as controls (mean SD binding; anti-a 0.78
0.37%, anti-y 3.31 1.65%, anti-j 3.41
1.29%).
Finally, sera samples from 8 patients with pri-
mary IgA nephropathy were tested for antimesangial
antibodies by indirect immunofluorescence with
sections of normal human kidney and fluorescein-
isothiocyanate-conjugated goat antihuman IgG
(H&L) antiserum.
Results
Serum immunoglobulin and complement concen-
trations (Table 1). Serum IgA was elevated (> 4.0 g/
liter) in 3 8.7% of the patients with primary IgA ne-
phropathy, 87.5% of the patients in group 2, and
20.0% of the patients with HSP. Serum 1gM was
elevated (> 2.0 g/liter) in 34.7%, 62.5%, and 20.0%,
respectively. Elevations in IgG (> 16.0 g/liter) were
less common (10.7%, 25.0%, and 0%, respectively).
Serum C3 concentrations were normal in patients
with IgA nephropathy and HSP but were low (<
0.65 glliter) in 50.0% of the patients with IgA gb-
merulonephritis and alcoholic cirrhosis. Serum Clq
concentrations were normal in all three groups. The
abnormalities in immunoglobulin and C3 concentra-
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Table 1. Basic clinical, immunofluorescent (IF), and serologic featuresa
Group 1 Group 2 Group 3
Number studied 78 10 6
Meanage,yr 33.3 47.4 39.5
Sex(M:F) 3.3 9.0 1.0
Glomerular IF deposits, %
IgA 100 100 100
IgG 22 50 0
1gM 43 63 40
C3 82 90 100
Clq 14 50 20
Serum concentration5
1gA(1.Oto4.Og/Iiter) 3.8 1.3 5.8 2.0 3.6 3.1
IgG (6.0 to 16.0 g/liter) 11.9 4.5 14.0 4.1 9.6 3.4
IgM(0.8to2.Og/liter) 1.7 0.9 4.1 2.8 1.5 1.0
C3 (0.65 to 1.25 g/liter) 0.99 0.17 0.71 0.21 1.01 0.14
Clq(80to120%ofpool) 106 16 111 15 107 28
a Group 1 is patients with primary IgA nephropathy; group 2, glomerulonephritis secondary to alcoholic cirrhosis and/or portal system-
ic shunt; group 3, Henoch Schonlein purpura.
b Values are the means SD. Parentheses contain the normal range.
tions persisted in serial sera samples from individ-
ual patients.
Detection of IgA polymers. Fractionation of sera
by Sephadex G200, Sepharose CL-6B, and sucrose
density gradient ultracentrifugation failed to detect
significantly increased amounts of> 8S IgA in pa-
tients with primary IgA nephropathy when com-
pared with controls [17]. In contrast, these tech-
niques detected "heavy" IgA in sera from all pa-
tients with alcoholic cirrhosis (Fig. 1).
Detection of CIC (Tables 2 and 3). With the
SPC1qA, IC were detected in one or more sera sam-
ples from 43.6% of the patients with primary IgA
nephropathy, 100% of the patients in group 2, and
50.0% of the patients with HSP. The mean amount
of IC was approximately the same in each group.
There was no significant correlation between the
detection of CIC in primary IgA nephropathy and
the presence of glomerular IgG, 1gM, or Clq; and
there was no correlation between CIC and serum
IgA, IgG, 1gM, or Clq concentrations (Tables 2 and
3). Serial IC determinations correlated with clinical
evidence of disease activity in approximately two
thirds of the patients. In particular, CIC were de-
tected in 18 (64.3%) of the 28 patients tested during
an episode of macroscopic hematuria. We noted
that IC were often present only intermittently in pa-
tients with primary IgA nephropathy and only dur-
ing the acute phase in HSP. In contrast, CIC were
almost always detectable in patients with IgA gb-
merulonephritis associated with alcoholic cirrhosis.
Twenty-two IC-positive patients had five or more
determinations performed over 6 to 24 months; 81%
of group 2 sera (5 patients), 65% of group 1 sera(14
patients), and 50% of group 3 sera (3 patients) were
positive during this study period. Representative
examples of serial studies in patients from each of
the three groups are illustrated in Figs. 2, 3, and 4.
Determination of IC size. Sucrose density gradi-
ent fractionation of test sera showed the IC to be of
intermediate (9 to 17S) size (Fig. 5), with no appar-
ent differences between the three groups.
IdentUication of immunoglobulin class of IC.
This was possible in 17 patients; 11 with primary
IgA nephropathy, 5 with IgA glomerulonephritis
and alcoholic cirrhosis, and 1 with HSP. In all of
gM I gG
$
Gradient volume, %
8
=
0
0
0
C
0
0
60 80
Fig. 1. Fractionation of sera from patients with primary IgA ne-
phropathy (a), glomerulonephritis associated with alcoholic cir-
rhosis (b) and from a control subject (c) by sucrose density gradi-
ent ultracentrifugation.
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Table 2. Detection of circulating immune complexes (CIC) by
solid phase Clq RiM
CIC Group 1 Group 2 Group3
Patients positive, % 43.6 100 50.0
Amount', jig AHG
equiv./ml 23.8 25.3 23.3 23.1 20.3 11.4
Size 9tol7S 9tol7S 9tol7S
Ig class (N 17) IgA 5
lgG4
IgG,Ml
IgA,G,Ml
IgA 1
IgA,G2
IgG,Ml
IgA,G,Ml
IgA 1
a Groups are defined in Table 1.
Values refer to mean SD.
Table 3. Circulating immune complexes (CIC) in patients with
primary IgA nephropathy (group 1)
IgA IgG 1gM Clq
IC positive
Glomerular deposits (%) 100 12 52 15
Serumconcentrationa 3.8 13.3 1.8 106
IC negative
Glomerular deposits 100 29 37 12
Serum concentrationa 3.7 10.9 1.7 106
a Mean values, units given in Table 1
these sera samples, the binding of heavy chain spe-
cific antisera exceeded the mean + 2 SD binding in
the control group. The results are shown in Table 2.
IgA was present in 11/17; alone in 7 and combined
with igG and/or 1gM in 4. IC of mixed immuno-
globulin class were most common in patients from
group 2. The same immunoglobulins were present
in the glomerular deposits in 11 of the 17 pa-
tients studied.
I
In vitro studies showed the SPC1qA to be rela-
tively insensitive in the detection of aggregated ()
colostral and myeloma IgA (' 1000 sg MgA/ml;
compared with > 5 to 10 g MgG/ml).
Correlation with serum cryoglobulins. Cryoglob-
ulins were detected in 9/14 patients with primary
IgA nephropathy, 2/4 patients in group 2 and 2/2 pa-
tients with HSP. CIC were detected by the SPC1qA
in 10 (76.9%) of the 13 patients with cryoglobulins.
Identification qf specific antibodies. Routine
screening failed to detect an increased incidence of
rheumatoid factor or of serum antibodies to IgA.
Similarly, none of the sera tested exhibited anti-
mesangial antibody activity. Eleven patients with
primary IgA nephropathy showed a significant tem-
poral rise in antibody titers to specific infectious
agents; herpes simplex in 4, streptococcus in 3,
mycoplasma pneumoniae in 2, influenza in 1, and
Epstein Barr virus in 1. It was more common, how-
ever, for patients with hematuria to have unspeci-
fied upper respiratory tract infections. Intercurrent
E. coli urinary tract infections were documented in
6 patients; 3 with primary IgA nephropathy, 2 with
IgA glomerulonephritis and alcoholic cirrhosis, and
1 with HSP. Patients with alcoholic cirrhosis had
increased serum antibody titers to all E. coli sero-
types tested. Only the 07 titers were increased in
patients with primary IgA nephropathy (Table 4).
Serum anti-BSA antibodies were also found to be
elevated in patients with alcoholic cirrhosis and to a
lesser extent in patients with primary IgA nephrop-
athy (Table 4). The immunoglobulin class of this
antibody was determined in 14 patients; 1gM anti-
I
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Fig. 2. Serial measurement of circulating immune complexes
(IC) in a patient with primary IgA nephropathy.(H'uria = hematuria)
Jun. Aug. Oct. Dec. Feb. Apr. Jun.
'78 '79
Fig. 3. Serial measurement of circulating immune complexes
(IC) in a patient with glomerulonephritis associated with alco-
holic cirrhosis. (H'uria = hematuria.)
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Sucrose density gradient fractions
Fig. 5. Determination of size of circulating immune complexes
(IC) by solid-phase Clq radioimmunoassay of sucrose density
gradient fractions. Primary IgA nephropathy (.—.), control(.----.).
body was identified in 9, IgA in 2, IgA, M in 2, and
IgG,M in 1.
Discussion
This study confirms the reported similarities be-
tween IgA nephropathy, HSP, and glomerulone-
phritis associated with alcoholic cirrhosis [5, 6, 13,
14]. All of these conditions have mesangial IgA de-
posits, usually accompanied by C3. 1gM deposits
were present in approximately 50% of the patients
in each group, but IgG and Clq were found fre-
quently only in the group with glomerulonephritis
and alcoholic cirrhosis. Patients with elevated
serum IgA concentrations were found in each group
(group 2 > 1 > 3), and similar findings were noted
for 1gM. Fractionation studies did not identify an
increase in polymeric forms of IgA in patients with
primary IgA nephropathy. This contrasts with the
findings of Lopez-Trascasca et al [25] and may re-
flect differences in fractionation techniques or pa-
tient selection. Certainly, we and others [2, 26] have
not been able to identify the secretory piece in the
glomerular immune deposits. In addition, we have
found that lowering the serum IgA and 1gM concen-
trations with phenytoin therapy has no effect on
persistence of the glomerular deposits or on disease
activity [17]. These findings suggest that the eleva-
tions in serum IgA are not of primary pathogenic
importance.
Most of the clinical and immunopathologic fea-
tures of these conditions suggest the glomerular
deposition of IC. The detection of CIC in HSP and
in glomerulonephritis secondary to alcoholic liver
disease has already been reported [14, 27—30]. In
contrast, previous attempts to detect CIC in pa-
tients with primary IgA nephropathy have been
largely unsuccessful [19, 27, 29, 31], but the number
of patients in these series was small. The only ex-
ception to this is the study of Gluckman et al [32] in
which IC were detected by polyethylene glycol pre-
cipitation and inhibition of complement dependent
lymphocyte rosette formation in 29% and 58%, re-
spectively, of sera from 40 patients with IgA ne-
phropathy. In the present study, CIC were detected
by SPC1qA in 44% of patients with primary IgA ne-
phropathy, 50% of patients with HSP, and 100% of
patients with glomerulonephritis secondary to alco-
holic cirrhosis. The amounts of IC were similar in
each group, and all IC were of intermediate (9 to
17S) size. In general, serial IC determinations cor-
related with clinical evidence of disease activity—
IC detection often being transient or intermittent in
primary IgA nephropathy or HSP but usually con-
stant in patients with glomerulonephritis and alco-
holic cirrhosis. CIC correlated with the presence of
cryoglobulins but not with increased serum IgA or
1gM concentrations. The IC were shown to contain
IgA and/or IgG, 1gM being less common and never
occurring alone. IC of mixed immunoglobulin class
were most common in patients with glomerulone-
phritis secondary to alcoholic cirrhosis. The overall
correlation between the class of immunoglobulin(s)
in the CIC and in the glomerular deposits was in-
complete, although these initial results support the
suggestion that the glomerular deposits may be de-
rived from CIC. It should be noted that CIC have
also been detected in patients who have liver dis-
ease without overt glomerulonephritis [33, 34] and
15
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Fig. 4. Serial measurement of circulating immune complexes(IC) in a patient with Henoch Schonlein purpura.
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Table 4. Identification of serum antibodies toE. coli and bovine serum albumin (BSA)
Groupsa
—
Anti-E. coli
geometric mean titers
AntiBSAb
% binding01 06 07 018 075
Controls (N = 30,80)
PrimarylgAnephropathy(N 74,66)
Alcoholic cirrhosis (N = 12, 28)
106
128
430
134
112
230
69
160
860
79
57
157
38
44
100
6.8 1.8
8.0 4.0
8.6 2.9
N denotes number of samples tested, with the first number referring to the anti-E. coli sampling and the second referring to the anti-
BSA sampling
b Values are the means SD.
that it is not yet possible to identify which IC are
"nephritogenic." Levinsky and Barratt [30] have
suggested that only IgG class IC are nephritogenic
in children with HSP, but no renal biopsy informa-
tion was given to substantiate this further.
Similarly, there is no satisfactory assay for the
specific detection of IgA class IC. Modifications to
the bovine conglutinin assay (McKenzie et al, to be
published), the Raji cell assay [34], and the latex-Ig
assay [30] have been proposed, but the data is still
limited. The detection of IgA class IC by SPC1qA in
the present study is perhaps unexpected in view of
the supposed inability of IgA to activate com-
plement via the classical pathway [35]. IgGi, IgG3,
and 1gM are known to fix Clq [35], and the SPC1qA
reactivity is presumably due to greater or lesser
amounts of these immunoglobulins present with
IgA in the CIC. False-positive results from non-IC
reactants such as endotoxin, DNA, and C-reactive
protein can be eliminated because these are not de-
tected by the SPC1qA [19]. The sucrose density gra-
dient data provides additional confirmation that the
assay is measuring IC immunoglobulin, although
the findings of Germuth and Rodriguez suggest that
somewhat larger (> 106 dalton) IC preferentially lo-
calize in the mesangium [36].
It was clear in this study that glomerular immune
deposits can persist long after CIC become unde-
tectable. This is also true in systemic lupus erythema-
tosus and in glomerulonephritis secondary to infec-
tive endocarditis [20] where "layering" of non-IC
antigen or antibody onto the existing deposits has
been invoked. Final confirmation of IC mediation in
IgA nephropathy rests with the detection of anti-
gen. This is notoriously difficult because the antigen
is likely to be masked by antibody in excess [37]. In
this study, we could find no evidence of autoanti-
body production to endogenous antigens, that is,
IgG, IgA, or mesangium. Instead, certain exoge-
nous antigens were implicated indirectly by the de-
tection of elevated titers of specific antibody espe-
cially in relation to acute exacerbations associated
with macroscopic hematuria. These included res-
piratory tract pathogens (for example, mycoplasma
pneumoniae and influenza virus), gut flora antigens
(E. coli), and dietary antigens (BSA).
The data suggest that IgA nephropathy may be
mediated by many common exogenous antigens. It
seems likely that the nature of the antigen is less
important that the integrity of the normal mecha-
nisms governing antigen entry and removal. This is
at present best exemplified by the secondary forms
of IgA nephropathy, that is, glomerulonephritis sec-
ondary to celiac disease and defective antigen ex-
clusion at the gut mucosa; glomerulonephritis sec-
ondary to alcoholic liver disease with defective he-
patic sequestration of antigens and CIC; and
glomerulonephritis with portal systemic shunts by-
passing the hepatic circulation. We have recently
succeeded in establishing an experimental model of
IgA nephropathy in rats with carbon-tetrachloride-
induced cirrhosis [38], and this model may prove
useful in studying the factors that influence IC for-
mation and sequestration. Rifai et al [39] have also
reported an animal model of IgA nephropathy that
is based on the mesangial deposition of IgA class
IC. These authors were able to induce nephritis in
mice with IC formed in vitro or in vivo from poly-
meric IgA (antibody) and dinitrophenol (DNP)-BSA
(antigen).
Our inability to demonstrate CIC in 56% of pa-
tients with primary IgA nephropathy may simply re-
flect the timing of IC determination or the limited
sensitivity of the IC assay. Other mechanisms,
however, should also be considered. For example,
it is possible that the mesangial deposits in these
patients are derived from IgA polymers or aggre-
gates [25] or that the IgA is reacting with a "planted
antigen" [8]. Neither of these mechanisms would
require the participation of CIC, and at this point no
claim can be made for a unifying pathogenesis.
It is hoped that these and other studies will ulti-
mately lead to an etiologic classification of IgA ne-
phropathy. Data on HLA associations [40] and re-
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ported abnormalities in cellular immunity [41] also
need to be investigated further. Until then, IgA ne-
phropathy must be regarded as a syndrome, and ra-
tional advances in therapy are unlikely.
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